Current cell-culture methods for manufacturing biologics, particularly gene therapies, often suffer from inefficiencies and scalability challenges, leading to high production costs and limited availability of these advanced therapeutics. Traditional transfection methods can also disrupt cell processes, negatively impacting yield and quality.

Kolibri provides an acoustic transfection unit designed to enhance the efficiency and scalability of viral vector production for gene therapies. Their technology utilizes acoustic waves to concentrate cells into smaller working volumes, improving cell productivity and cost-effectiveness. The controlled acoustic environment minimizes shear stress, ensuring cell viability and maximizing transfection efficiency. This approach allows for higher viral vector titers with less disruption to cell processes, ultimately leading to increased yields and reduced batch requirements.

Acoustic cell manipulation for low-shear transfection within 15 minutes

Cell-agnostic platform applicable to various cell types and therapy modalities

Scaled-down design concentrating cells into 10x smaller working volumes

Controlled acoustic waves for media circulation and minimal shear stress

Seamless integration into existing biomanufacturing processes

Increased viral vector titers and higher yields without increasing starting materials

The primary target audience includes biopharmaceutical companies and research institutions involved in the development and manufacturing of gene therapies and other biologics.